GCC Cancer Therapeutics Market Report (2021–2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The Cancer Therapeutics Market size is expected to reach US$ 2,666.24 million by 2031 from US$ 1,302.01 million in 2024. The market is estimated to record a CAGR of 10.87% from 2025 to 2031.

Executive Summary and GCC Cancer Therapeutics Market Analysis:

The cancer therapeutics market in GCC is experiencing significant growth driven by several key factors, including significant advancements in healthcare infrastructure and an increase in the prevalence of cancer. The region is known for its economic wealth, and it has made strides in developing its healthcare sector to meet the rising demands of its aging population. Owing to the continuous evolution of healthcare systems, rising cancer incidence, burgeoning government support, and an increased focus on cancer care, the GCC region is experiencing substantial growth in the cancer therapeutics market. The demand for innovative cancer treatment modalities such as immunotherapies and personalized medicine is rising in GCC countries, and investments in healthcare systems and awareness programs are aiding in improved access to these therapies.

GCC Cancer Therapeutics Market Segmentation Analysis:

Key segments that contributed to the derivation of the cancer therapeutics market analysis are therapy type, indication, and distribution channel.

By therapy type, the cancer therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment dominated the market in 2024. In terms of indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment held the largest share of the market in 2024. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the market in 2024.

GCC Cancer Therapeutics Market Outlook

A significant rise in cancer cases in the region drives the need for cancer therapeutics. According to the government of UAE, ~4,500 new cases of cancer are reported every year in the country. The International Agency for Research on Cancer stated that the UAE recorded 4,807 new cancer cases in 2020. As per GLOBOCAN 2020 data, the country recorded ~1,030 new breast cancer cases, representing 21.4% of all new cases. The demand for cancer treatments, both conventional and innovative, is surging due to increasing cancer cases, coupled with an aging population and lifestyle factors that contribute to cancer risks, such as smoking and poor dietary habits.

Governments of various countries of the GCC are investing heavily in healthcare infrastructure and cancer control programs. For instance, the government of Kuwait has been actively investing in efforts to enhance the cancer treatment infrastructure. The Ministry of Health (MOH) has prioritized cancer care by establishing specialized treatment centers such as the Kuwait Cancer Control Center, which provides a wide range of services, including chemotherapy and immunotherapy. In October 2021, the National Bank of Kuwait (NBK) launched an annual campaign during breast cancer awareness month to promote women's health. The campaign is part of the Bank's ongoing campaign to raise social awareness regarding breast cancer and promote its ways of prevention.

GCC Cancer Therapeutics Market Country Insights

Based on region, the Gulf Cooperation Council (GCC) cancer therapeutics market is further segmented into Saudi Arabia, UAE, Kuwait, Oman, Qatar, and Bahrain. Saudi Arabia held the largest share in 2024.

The growth of the cancer therapeutics market in Saudi Arabia is driven by rising cancer incidence, growing healthcare infrastructure, and an increasing aging population. Saudi Arabia has been experiencing an upsurge in the incidence of cancer; the number of cancer-related deaths has also increased in the country. As per GLOBOCAN 2020 data, the country recorded ~27,885 new cancer cases, and the number is expected to rise to 60,429 by 2040. Also, the number of people aged 80 or more is expected to reach 1.6 million, i.e., 4% of the total population by 2050. Lifestyle changes such as increased tobacco use and poor dietary habits further elevate cancer risk in the Saudi population.

GCC Cancer Therapeutics Market Company Profiles

Astellas Pharma Inc; Eli Lilly and Co; Novartis AG; Merck KGaA.; Johnson & Johnson; AstraZeneca; Julphar Pharmaceuticals; Bristol Myers Squibb; SPIMACO ADDWAEIH; and Gulf Investment Corporation are among the key players operating in the market. These companies are engaged in collaborative drug development to bring novel therapeutics for cancer in the market, aiming to stay ahead on competitive edge.

GCC Cancer Therapeutics Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

Company websites, annual reports, financial statements, broker analyses, and investor presentations Industry trade journals and other relevant publications Government documents, statistical databases, and market reports News articles, press releases, and webcasts specific to companies operating in the marketNote:All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

Business Market Insights conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:

Refine findings from secondary research Enhance the expertise and market understanding of the analysis team Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:

Industry stakeholders:

Vice Presidents, business development managers, market intelligence managers, and national sales managers External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise Key Sources Referred:

The World Bank World Development Indicators: Arab World World Health Organization Regional Office for Eastern Mediterranean (WHO-EMRO) Global Cancer Observatory Qatar Cancer Society